4 completed, 2 active not recruiting, 2 unknown. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Active not recruiting 2, Unknown 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Malignant Neoplasm of Breast: new trials by email Literature Review of Malignant Neoplasm of Breast trials Research Report on Malignant Neoplasm of Breast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza] - Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Active not recruiting | Institut fuer Frauengesundheit | 11 | 2022-07-30 | 2024-05-07 |
| Therapeutic Dose Monitoring (TDM) of Tamoxifen Tamoxifen 20 mg - Breast Cancer, Breast Carcinoma | Phase 2 | Unknown | Karolinska University Hospital | 40 | 2022-04-04 | 2022-05-25 |
| Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) Imprime PGG, Pembrolizumab - Malignant Neoplasm of Breast | Phase 2 | Completed | HiberCell, Inc. | 26 | 2021-11-09 | 2023-06-22 |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Pembrolizumab, nab-paclitaxel, Epirubicin - Malignant Neoplasm of Breast | Phase 2 | Completed | Institut fuer Frauengesundheit | 53 | 2018-03-23 | 2021-04-08 |
| Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer Trastuzumab, Ibrutinib 560 mg, Ibrutinib 840 mg - Breast Neoplasms, Malignant Neoplasm of Breast | Phase 1 / Phase 2 | Active not recruiting | US Oncology Research | 34 | 2017-11-29 | 2024-12-06 |
| Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Paclitaxel, Alisertib - Breast Cancer, Breast Carcinoma | Phase 2 | Completed | US Oncology Research | 169 | 2015-02-12 | 2024-10-09 |
| Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer Genomically Directed Monotherapy, Observation/Standard Therapy - Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Completed | Bryan Schneider, MD | 193 | 2014-04-03 | 2023-09-28 |
| ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes ICG Fluorescence technique - Malignant Neoplasm of Breast | Phase 2 | Unknown | Pulsion Medical Systems SE | 125 | 2011-09-01 | 2011-07-18 |
Breast Neoplasms (8) · Triple Negative Breast Neoplasms (2)
Breast Diseases (8) · Neoplasms (8) · Neoplasms by Site (8) · Skin Diseases (8) · Skin and Connective Tissue Diseases (8)
pembrolizumab (3) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · BTH1677 (1) · Cyclophosphamide (1) · Epirubicin (1) · Indocyanine Green (1) · MLN 8237 (1) · Observation (1) · Standard of Care (1) · Tamoxifen (1) · Trastuzumab (1) · ibrutinib (1) · olaparib (1)
Institut fuer Frauengesundheit (2) · US Oncology Research (2) · Bryan Schneider, MD (1) · HiberCell, Inc. (1) · Karolinska University Hospital (1) · Pulsion Medical Systems SE (1)
United States (4) · Germany (3) · Sweden (1)
Alison Stopeck, MD (1) · Bryan Schneider, M.D. (1) · Diethelm Wallwiener, Prof. Dr. (1) · Elham Hedayati, MD PhD (1) · Joyce A. O'Shaughnessy, MD (1) · Joyce O'Shaughnessy, MD (1) · Peter A Fasching, MD, Prof. (1) · Peter A. Fasching, MD, Prof. (1)
PMID 32644110, PMID 33877311, PMID 34910554, PMID 38745646, PMID 42504645
2016 (1)